Tryptamine Therapeutics (AU:TYP) has released an update.
In a recent update, Tryptamine Therapeutics Limited reported that director Jason Carroll increased his direct shareholding by acquiring 1 million ordinary fully paid shares at $0.025 each, totaling an investment of $25,000. This purchase, made on the market, brought Carroll’s total number of ordinary shares to 33.5 million. No other changes in securities or contracts were reported.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
